Henry Mugerwa
A5112330039- HIV/AIDS Research and Interventions
- HIV/AIDS drug development and treatment
- HIV Research and Treatment
- COVID-19 Clinical Research Studies
- HIV-related health complications and treatments
- SARS-CoV-2 and COVID-19 Research
- Ethics in Clinical Research
- Hepatitis C virus research
- Long-Term Effects of COVID-19
- Pneumocystis jirovecii pneumonia detection and treatment
- HIV, Drug Use, Sexual Risk
- Tuberculosis Research and Epidemiology
- Pharmacological Effects and Toxicity Studies
- Diabetes Management and Education
- Malaria Research and Control
- Pregnancy and Medication Impact
- Adolescent Sexual and Reproductive Health
- Biomedical Ethics and Regulation
- Diagnosis and treatment of tuberculosis
- Adolescent and Pediatric Healthcare
- Drug Transport and Resistance Mechanisms
- Virus-based gene therapy research
- Chronic Obstructive Pulmonary Disease (COPD) Research
- COVID-19 Impact on Reproduction
- Antibiotics Pharmacokinetics and Efficacy
Joint Clinical Research Centre
2012-2025
Gulu Hospital
2022
Uganda Virus Research Institute
2022
University of Nottingham
2019-2020
Makerere University
2012-2020
University of Michigan
2019
Lancet Laboratories
2019
Soroti University
2019
University of Kent
2019
Medical Research Council
2018
The World Health Organization recommends dolutegravir with two nucleoside reverse-transcriptase inhibitors (NRTIs) for second-line treatment of human immunodeficiency virus type 1 (HIV-1) infection. Evidence is limited the efficacy this regimen when NRTIs are predicted to lack activity because drug resistance, as well recommended switch an NRTI from tenofovir zidovudine.
BackgroundWHO guidelines recommend dolutegravir plus two nucleoside reverse transcriptase inhibitors (NRTIs) for second-line HIV therapy, with NRTI switching from first-line tenofovir to zidovudine. We aimed examine whether is non-inferior darunavir, the best-in-class protease inhibitor drug, and maintaining in therapy zidovudine.MethodsIn this prospective, multicentre, open-label, factorial, randomised, non-inferiority trial (NADIA), participants confirmed treatment failure (HIV-1 RNA ≥1000...
Abstract Background Cipargamin (KAE609) is a potent antimalarial in phase II trial. Here we report efficacy, pharmacokinetics, and resistance marker analysis across range of cipargamin doses. These were secondary endpoints from study primarily conducted to assess the hepatic safety (hepatic data are reported elsewhere). Methods This II, multicenter, randomized, open-label, dose-escalation trial was sub-Saharan Africa adults with uncomplicated Plasmodium falciparum malaria. monotherapy given...
Cross-resistance after first-line antiretroviral therapy (ART) failure is expected to impair activity of nucleoside reverse-transcriptase inhibitors (NRTIs) in second-line for patients with HIV, but evidence the effect cross-resistance on virological outcomes limited. We aimed assess association between activity, predicted by resistance testing, NRTIs used and treatment infected HIV.We did an observational analysis additional data from a published open-label, randomised trial ART (EARNEST)...
Introduction Antiretroviral therapy (ART) has changed the course of HIV/AIDs by enabling patients to live longer, raising concern co- existence HIV with other chronic illnesses, notably non-communicable diseases (NCDs). NCDs are on rise in developing countries and evidence shows higher occurrence among people living (PLHIV). In Uganda, burden PLHIV remains largely unquantified. Objective To determine prevalence hypertension, osteoporosis, diabetes mellitus, renal impairment, asthma,...
Background While the proportion of HIV-positive children (under 15 years) enrolled on antiretroviral therapy (ART) has increased in recent years, up to 60% started ART do not achieve virological suppression. We set out determine factors associated with non-suppression among living HIV receiving at a peri-urban care clinic Kampala, Uganda. Method This was retrospective cohort study conducted pediatric HIV/AIDS Joint Clinical Research Centre (JCRC) Three hundred (300) (0–14 were randomly...
Ritonavir-boosted atazanavir is a victim of drug-drug interaction with rifampicin, key component antitubercular treatment. In recent dose escalation clinical trial, we showed that increasing atazanavir/ritonavir to 300/100 mg b.i.d. compensates for reduced drug exposure in plasma due but the intracellular effects remained unexplored. This sub-study investigated penetration and dolutegravir into peripheral blood mononuclear cells (PBMC). Twenty-six healthy volunteers living HIV, virologically...
The impact on immunogenicity and efficacy of SARS-CoV-2 vaccination in people with prior COVID-19 could differ depending timing number doses. VATICO study randomized 66 hospitalized recovered individuals to receive either immediate or deferred vaccination, one two doses mRNA vaccines. We measured binding neutralizing antibodies against at enrollment longitudinally. Median (IQR) time from infection first was 68 (53–75) days the group, 151 (137–173) group. At week 48, vaccine did not influence...
Millions of HIV-infected people worldwide receive antiretroviral therapy (ART) in programmes using WHO-recommended standardised regimens. Recent WHO guidelines recommend a boosted protease inhibitor plus raltegravir as an alternative second-line combination. We assessed whether this treatment option offers any advantage over the standard two nucleoside reverse-transcriptase inhibitors (NRTIs) combination after 144 weeks follow-up typical programme settings.
Ritonavir-boosted atazanavir (ATV/r) and rifampicin are mainstays of second-line antiretroviral multiple anti-TB regimens, respectively. Rifampicin induces CYP3A4, a major enzyme involved in metabolism, causing drug-drug interaction (DDI) which might be exaggerated pregnancy. Having demonstrated that increasing the dose ATV/r from once daily (OD) to twice (BD) non-pregnant adults can safely overcome this DDI, we developed pregnancy physiologically based pharmacokinetic (PBPK) model explore...
Abstract Background The novel anti-malarial cipargamin (KAE609) has potent, rapid activity against Plasmodium falciparum . Transient asymptomatic liver function test elevations were previously observed in cipargamin-treated subjects two trials: one malaria patients Asia and volunteers with experimentally induced malaria. In this study, the hepatic safety of given as single doses 10 to 150 mg 50 once daily for 3 days was assessed. Efficacy results, frequency treatment-emerging mutations atp4...
Abstract Background Critical drug-drug interactions (DDI) and hepatotoxicity complicate concurrent use of rifampicin protease inhibitors. We investigated whether dose escalation atazanavir/ritonavir could safely overcome the DDI with rifampicin. Methods DERIVE (NCT04121195, EDCTP) was a dose-escalation trial in people human immunodeficiency virus (HIV) on atazanavir/ritonavir-based antiretroviral therapy (ART) Uganda. Four intensive pharmacokinetic (PK) visits were performed: PK1 300/100 mg...
Chronic obstructive pulmonary disease (COPD) is a leading cause of death and disability globally. Both cigarette smoking HIV have been identified as independent risk factors for COPD. We used data from the strategic timing antiretroviral treatment (START) Pulmonary Substudy to quantify impact on rate lung function decline in HIV.
From 2006 to 2011, a cohort study was conducted among 1000 children resident in urban and rural settings of Uganda ascertain compare the response antiretroviral therapy (ART) versus factors associated with this response. Clinical, immunological, virological parameters were ascertained at baseline weeks 24, 48, 96, 144 after ART initiation. Adherence assessed enrollment by self-report (SR) pill counts (PC). Overall, 499/948 (52.6%) areas, 504/948 (53.1%) male, their mean age 11.9±4.4 years...
Uganda's Ministry of Health registered a 12% increase in new Tuberculosis (TB) cases between 2001 and 2005. Of these, 20% were from Kampala district most Mulago national referral hospital where the largest oldest medical school is found. Medical students are likely to have an increased exposure TB infection due their training hospitals compared other university students. The study prevalence associated factors among undergraduate veterinary Makerere University, Uganda.This was...
Self-management of HIV is a desirable goal for the millions adolescent persons living with (PLWH). Adolescent PLWH continue to experience poor care outcomes, primarily due rates medication adherence and retention in care, highlighting need develop self-management skills. The aim our study was examine adolescent, caregiver, health provider perceptions roles, barriers, facilitators. Swendeman et al.'s framework chronic diseases guided analyses. Participant narratives highlighted their...
Abstract Introduction Failure on second-line antiretroviral therapy (ART) with protease inhibitor (PI) mutations (VF-M) is the rise. However, there a paucity of information factors associated this observation in low-income countries. Knowledge underlying critical if we are to minimize number PLHIV switched costly third-line ART. Our study investigated VF-M. Methods We conducted matched case–control analysis patients' records kept at Joint Clinical Research Center, starting from January 2008...
Limited viral load (VL) testing in human immunodeficiency virus (HIV) treatment programs low-income countries often delays detection of failure. The impact remaining on failing protease inhibitor (PI)-containing regimens is unclear.We retrospectively tested VL 2164 stored plasma samples from 386 patients randomized to receive lopinavir monotherapy (after initial raltegravir induction) the Europe-Africa Research Network for Evaluation Second-line Therapy (EARNEST) trial. Protease genotypic...
The heightened vulnerability of adolescents to poor HIV care outcomes underscores the need for interventions that create and promote self-management behavioral skills. Adolescents living with (ALHIV) experience a complex array physical, emotional, social challenges constrain their self-care, but majority existing psychosocial programs focus primarily on medication adherence. Understanding adolescents' self-care needs, challenges, preferences is necessary developing effective culturally...
Abstract Background Identifying factors that determine the frequency of latently infected CD4+ T cells on antiretroviral therapy (ART) may inform strategies for human immunodeficiency virus (HIV) cure. We investigated role count at ART initiation HIV persistence ART. Methods Among participants Strategic Timing Antiretroviral Treatment Study, we enrolled people with (PWH) who initiated T-cell counts 500–599, 600–799, or ≥ 800 cells/mm3. After 36–44 months ART, levels total HIV-DNA,...